Iodine-125 brachytherapy alone for advanced primary parotid gland carcinoma

This study aimed to evaluate the efficacy of iodine-125 (125I) brachytherapy alone for the treatment of advanced parotid gland carcinoma and to identify predictors of tumour control and patient survival. Primary parotid gland carcinoma patients (n=23) treated with 125I brachytherapy alone between 1 October 2005 and 31 July 2013 at Peking University Stomatology Hospital were enrolled in this retrospective study. All had clinical stage IV disease. The prescribed dose was 60 –160Gy. The local control rate, survival rate, and predictors of the prognosis were evaluated.

Source: International Journal of Oral and Maxillofacial Surgery - September 28, 2017 Category: ENT & OMF Authors: C. Zhou, J. Zhang, J.-G. Zhang, S.-M. Liu, L. Zheng, M.-W. Huang, Y. Shi, X.-M. Lv Tags: Clinical Paper Source Type: research